New Hope for Patients with Breast Cancer Including Patients with Brain Metastases

Nancy Lin presents the DESTINY-Breast12 trial studied HER2-positive metastatic breast cancer patients, including those with and without brain metastases. The trial confirmed trastuzumab deruxtecan (T-DXd) as effective, with a 63% response rate in the non-brain metastasis cohort and a one-year survival rate of 90% for both groups, thereby solidifying the intracranial activity of T-DXd.